BCL11B Knockout AGS Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the AGS human gastric adenocarcinoma cell line, designed for targeted disruption of the BCL11B gene. This polyclonal pool consists of a heterogeneous mixture of edited cells, enabling loss-of-function studies without clonal isolation. The knockout was generated using CRISPR/Cas9-mediated gene disruption, resulting in a versatile model for investigating BCL11B-dependent cellular processes.
The AGS cell line originates from a gastric adenocarcinoma patient and serves as a widely used in vitro model for gastric cancer research. As cancerous epithelial cells, AGS retains key features of gastric adenocarcinoma, including dysregulated proliferation and apoptosis, making it a relevant system to study oncogenic signaling networks and to evaluate potential therapeutic interventions.
BCL11B encodes a zinc finger transcriptional repressor that functions by recruiting NuRD/HDAC complexes, including MTA1 and HDAC1/2, to mediate chromatin remodeling and gene silencing. Its expression is regulated by upstream signals such as NOTCH1, IL-7, and TCF7, and it directly represses target genes like CDKN1A, ID2, BCL2L1, and TCF3. BCL11B also interacts with transcriptional regulators RUNX1 and NR2F2. Through these molecular interactions, BCL11B controls cell cycle progression and apoptotic balance, primarily via HDAC-dependent transcriptional repression. In the NOTCH signaling cascade, activated NOTCH1 intracellular domain associates with RBPJ and MAML to induce BCL11B transcription, which in turn modulates cellular outcomes.
In the AGS gastric adenocarcinoma background, BCL11B knockout is expected to disrupt its tumor-suppressive functions, potentially altering cell proliferation, survival, and sensitivity to chemotherapeutic agents. Loss of BCL11B-mediated repression may lead to upregulation of pro-proliferative genes and impaired apoptosis, providing insights into the molecular mechanisms of gastric cancer progression. This knockout model is particularly valuable for dissecting BCL11B??s role in NOTCH-driven transcriptional networks and for evaluating therapeutic strategies targeting the NuRD complex or BCL11B interactors.
This polyclonal knockout product is optimized for a broad range of research applications, including functional genomics studies, drug target validation, and mechanistic investigations of apoptosis and proliferation. Researchers can utilize this model in western blotting for protein expression analysis, RT-qPCR and RNA-seq for transcriptional profiling, ChIP-qPCR for chromatin occupancy, and functional assays such as MTT or BrdU proliferation assays, Annexin V or caspase-based apoptosis detection, and colony formation studies. The loss-of-function system enables robust and reproducible analysis of BCL11B-dependent pathways in gastric cancer. For further details, please contact Ascent Research.
